A biotechnology company developing a dual-acting molecule intended to restore liver function in patients with fatty liver disease.
Heureka Therapeutics has raised €500k across 1 funding round from 1 investor, most recently a Debt round in Mar 2026. Based in Copenhagen, Denmark; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-03-10 | Debt |
| €500k |
| BioInnovation Institute |
| View deal → |
